COMP <GO>
MDLN vs DXCM // RETURN ON INVESTED CAPITAL (ROIC)
Medline Inc. (NASDAQ) VS. DexCom Inc. (NASDAQ) • 15-METRIC TALLY: MDLN 4
— DXCM 7
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: DXCM
LAST: $32.00 (-1.14%) • MKT CAP: $42.07B
roic
8.20%
LAST: $79.93 (+1.67%) • MKT CAP: $30.16B
roic
21.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDLN VS. DXCM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDLN | DXCM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 60.10% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 8.20% | 21.60% | -13.40 | DXCM | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.3x | 25.2x | -4.90 | MDLN | /valuation <GO> |
| Free Cash Flow Yield | 3.08% | 3.57% | -0.49 | DXCM | /fcf-yield <GO> |
| Operating Margin | 7.80% | 19.60% | -11.80 | DXCM | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 17.90% | +50.10 | MDLN | /net-margins <GO> |
| Revenue Growth (YoY) | 11.50% | 15.60% | -4.10 | DXCM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.50 | 7.14 | -4.64 | DXCM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | DXCM | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.9 | 41.8 | -10.90 | DXCM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.11 | 1.10 | +0.01 | MDLN | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 30.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $42.07B | $30.16B | $11.91B | MDLN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDLN REV | DXCM REV | MDLN GROSS % | DXCM GROSS % | MDLN FCF | DXCM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $28.43B | $4.66B | 26.4% | 60.1% | $1.30B | $1.08B |
| FY 2024 | $25.51B | $4.03B | 27.3% | 60.5% | $1.42B | $630.7M |
| FY 2023 | $23.23B | $3.62B | — | — | $639.6M | $585.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDLN // BETA 1.11
DXCM // BETA 1.10